Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · ProShares

ProShares UltraShort Nasdaq Biotechnology (BIS)

Ticker BIS · · Holdings as of May 31, 2026

Expense ratio
0.95%$95/yr per $10k
5-yr return
−15.1%annualized
1-yr return
−46.1%as of Dec 2025
Net assets
$2.4Mall share classes
Holdings
9

Bottom line

Is BIS a good fund? The bottom line

BIS is an actively managed leveraged & inverse ETF from ProShares.

It charges 0.95% — about $95 a year on every $10,000 invested, cheaper than 82% of leveraged & inverse funds we track.

It returned −46.1% over one year, −15.1% a year over five years, −21.2% a year over ten (as of Dec 31, 2025, per its prospectus).

With $2.4 million in net assets and 9 holdings, its largest position is Repurchase Agreement (40.6%) and the top 10 make up 54% of the portfolio.

What stands out

  • Low cost: cheaper than 82% of leveraged & inverse peers

What to watch

  • Concentrated: top 10 holdings are 54% of assets
  • Small fund ($2.4 million) — small funds are likelier to close

Updated Nov 19, 2026

What BIS invests in

ProShares UltraShort Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index (the Index).

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. The Index includes companies listed on the Nasdaq Global Select Market or the Nasdaq Global Market (which include both U.S. and non-U.S. companies) that are included in the biotechnology or pharmaceuticals subsectors, according to the Industry Classification Benchmark. The biotechnology and pharmaceutical subsectors include companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development and manufacturers of prescription or over-the-counter drugs. Companies are selected based on market capitalization and liquidity. Selected companies are then…

From the fund's prospectus (filed Sep 25, 2026).

BIS performance

Fund calendar-year total returns, 2016–2025 2016: +22.0%; 2017: −37.2%; 2018: +5.0%; 2019: −40.8%; 2020: −56.0%; 2021: −14.8%; 2022: −2.5%; 2023: −6.3%; 2024: +5.0%; 2025: −46.1% +22% 2016 −37% 2017 +5% 2018 −41% 2019 −56% 2020 −15% 2021 −3% 2022 −6% 2023 +5% 2024 −46% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BIS−46.1%−15.1%−21.2%
Leveraged & Inverse median−7.7%−11.8%−13.5%

Source: Fund prospectus, as of Dec 31, 2025

Full BIS performance history →

What BIS costs

On a $10,000 investment, BIS's 0.95% expense ratio costs about $95 a year. The prospectus estimates $3,943 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full BIS fee table →

BIS top 10 holdings

#Holding% of fund
1Repurchase Agreement40.64%
2Repurchase Agreement25.57%
3Repurchase Agreement19.18%
4Repurchase Agreement14.06%
5N/a-3.64%
6N/a-3.75%
7N/a-10.52%
8N/a-11.12%
9N/a-16.39%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 54% of the fund. See all top 25 holdings and asset mix →

Alternatives to BIS

More funds like BIS →

BIS FAQ

What is the expense ratio of BIS?
BIS's expense ratio is 0.95%, which works out to about $95 a year for every $10,000 invested. The prospectus estimates total costs of $3,943 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BIS a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 82% of leveraged & inverse peers; concentrated: top 10 holdings are 54% of assets; small fund ($2.4 million) — small funds are likelier to close. This is general information, not personalized advice.
What does BIS hold?
BIS's largest holdings are Repurchase Agreement (40.6%), Repurchase Agreement (25.6%), Repurchase Agreement (19.2%), Repurchase Agreement (14.1%), N/a (-3.6%). It holds 9 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is BIS's 5-year return?
BIS returned −15.1% a year over the five years ending Dec 31, 2025, and −21.2% a year over ten years. Past performance does not guarantee future results.
Who manages BIS?
BIS is offered by ProShares through Proshares Trust.